Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.950 -0.100 (-4.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,034
Open 2.010
Bid (Size) 1.950 (100)
Ask (Size) 1.980 (200)
Prev. Close 2.050
Today's Range 1.950 - 2.040
52wk Range 1.170 - 2.710
Shares Outstanding 78,986,490
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 ↗
Innate Pharma (NASDAQ:IPHA) said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs... 
Via MarketBeat

Performance

YTD
+7.1%
+7.1%
1 Month
-12.2%
-12.2%
3 Month
+10.2%
+10.2%
6 Month
+18.9%
+18.9%
1 Year
-4.4%
-4.4%

More News

Read More
News headline image
Innate Pharma Announces Conference Call and Webcast
From Innate Pharma SA
Via Business Wire
Unusual volume stocks are being observed in Wednesday's session. ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
From Innate Pharma SA
Via Business Wire
News headline image
Outcome of Innate Pharma’s 2026 Annual General Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to participate in the Jefferies Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the D. Boral Capital Global Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the Kempen Life Sciences Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
From Innate Pharma SA
Via Business Wire

Frequently Asked Questions

Is Innate Pharma S.A. - American Depositary Shares publicly traded?
Yes, Innate Pharma S.A. - American Depositary Shares is publicly traded.
What exchange does Innate Pharma S.A. - American Depositary Shares trade on?
Innate Pharma S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Innate Pharma S.A. - American Depositary Shares?
The ticker symbol for Innate Pharma S.A. - American Depositary Shares is IPHA on the Nasdaq Stock Market
What is the current price of Innate Pharma S.A. - American Depositary Shares?
The current price of Innate Pharma S.A. - American Depositary Shares is 1.950
When was Innate Pharma S.A. - American Depositary Shares last traded?
The last trade of Innate Pharma S.A. - American Depositary Shares was at 09/09/26 04:00 PM ET
What is the market capitalization of Innate Pharma S.A. - American Depositary Shares?
The market capitalization of Innate Pharma S.A. - American Depositary Shares is 154.02M
How many shares of Innate Pharma S.A. - American Depositary Shares are outstanding?
Innate Pharma S.A. - American Depositary Shares has 154M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.